BioSight
Companies
Nkarta, Inc. logo

NKTX

NASDAQSOUTH SAN FRANCISCO, CA
Nkarta, Inc.

Nkarta develops NK cell therapies, a type of immunotherapy, for treating autoimmune diseases and other conditions. The company is in clinical development stage, with NKX019 as a key product candidate undergoing clinical trials. Nkarta's pipeline focuses on leveraging NK cell technology to address diseases where current treatment options are limited.

Price history not yet available for NKTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar